Welcome to Public Health On Call, a podcast from the Johns Hopkins Bloomberg School of Public Health,

where we bring evidence, experience, and perspective to make sense of today's leading health challenges.

If you have questions or ideas for us, please send an email to public health question at jhh.edu.

That's public health question at jhhu.edu for future podcast episodes.

This is Lindsay Smith-Rogers. Today, the topic is abortion, specifically the court decision in Texas that would

invalidate the approval of Mithapristone, otherwise known as Miphypricks. Dr. Reagan-McDonnell

Mosley joins us again on the podcast to discuss the decision. Dr. Mosley is an OBGYN and the CEO of

Power to Decide, a private, nonpartisan, non-profit organization that,

and I'm quoting here, works to ensure all people have the power to decide if, when, and under what circumstances to get pregnant and have a child.

She speaks with Dr. Sharfstein about the uncertainty caused by the decision and what could come next. Let's listen.

Dr. Reagan-McDonnell-Moseley, thank you so much for joining me in Public Health on

Call. We're recording this on a Sunday after pretty momentous court decision, or I should say maybe a

couple momentous court decisions that just happened a couple days ago.

Yes, thank you so much for having me.

So we've been waiting to see what this Texas court would do on Miphypristone,

and it delivered what the case had promised, in a sense, a very conservative judge,

essentially invalidating the approval of a medication that's been

pretty widely used for medication abortions. Yes, as a physician who focuses on reproductive

health and family planning issues, the Texas case is really dumbfounding. Medication abortion,

and specifically, Mephiproprristone has been on the market for longer

than I've even been a doctor for over 20 years. It has a huge proven safety record. It's safe and

effective to end an early pregnancy. And over 5 million people in the United States alone have used

...